Adoptive Immunotherapy of Patients with Metastatic Renal Cell Cancer Using Lymphokine‐Activated Killer Cells, lnterleukin‐2 and Cyclophosphamide: Long‐Term Results

Abstract

Long-term effects of LAK/IL-2/CPM therapy were not correlated with the maximal response observed 4 weeks after therapy. Although LAK/IL-2/CPM therapy appears suitable for use as induction therapy in RCC, our data suggest that long-term suppression will require surgical removal of remnant tumors or more intensive maintenance therapy.